Annovis Bio (ANVS) Assets (2019 - 2026)
Annovis Bio (ANVS) posted Assets of $16.2 million for Q1 2026, down 22.95% sequentially from $21.1 million in Q4 2025, and down 39.25% YoY from $26.7 million in Q1 2025.
Annovis Bio (ANVS) Assets (2019 - 2026) Analysis & Trends
Annovis Bio has reported Assets for 8 years, with the latest figure at $16.2 million in Q1 2026.
- Quarterly Assets fell 39.25% year-over-year to $16.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $16.2 million (down 39.25% YoY) and the FY2025 annual result came in at $21.1 million, up 51.39% from the prior year.
- Assets fell to $16.2 million in Q1 2026 per ANVS's latest filing, from $21.1 million in the prior quarter.
- Over five years, Assets peaked at $44.1 million in Q1 2022 and troughed at $5.0 million in Q2 2024.
- A 5-year average of $21.8 million and a median of $21.1 million in 2025 frame the typical range for Assets.
- The sharpest annual moves came in 2022 and 2024: Assets soared 639.28% in 2022, then plunged 77.88% in 2024.
- Over 5 years, Assets stood at $36.0 million in 2022, then slumped by 71.66% to $10.2 million in 2023, then soared by 36.42% to $13.9 million in 2024, then jumped by 51.39% to $21.1 million in 2025, then fell by 22.95% to $16.2 million in 2026.
- According to Business Quant data, Assets over the past three periods registered $16.2 million, $21.1 million, and $17.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 5.56 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 2.10 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.82 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 25.60 Bn |
| 10 | Annovis Bio | 66.78 Mn | 66.78 Mn | - | 22.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 16.24 Mn |
| Dec 31, 2025 | 21.08 Mn |
| Sep 30, 2025 | 17.19 Mn |
| Jun 30, 2025 | 21.45 Mn |
| Mar 31, 2025 | 26.74 Mn |
| Dec 31, 2024 | 13.93 Mn |
| Sep 30, 2024 | 14.36 Mn |
| Jun 30, 2024 | 5.05 Mn |
| Mar 31, 2024 | 7.81 Mn |
| Dec 31, 2023 | 10.21 Mn |
| Sep 30, 2023 | 10.22 Mn |
| Jun 30, 2023 | 22.82 Mn |
| Mar 31, 2023 | 25.55 Mn |
| Dec 31, 2022 | 36.02 Mn |
| Sep 30, 2022 | 37.12 Mn |
| Jun 30, 2022 | 39.97 Mn |
| Mar 31, 2022 | 44.10 Mn |
| Dec 31, 2021 | 46.00 Mn |
| Sep 30, 2021 | 47.65 Mn |
| Jun 30, 2021 | 49.50 Mn |